Day 9 (2): Pathophysiology of Ocular Inflammation Flashcards

1
Q

What is the immune system?

A
  • complex network of interacting cells, cell products and processes that work to defend the body against pathogens

Components:
1. Cellular components
- WBC: neutrophils, eosinophils, basophils, monocytes, lymphocytes
- Dendritic cells
- Natural Killer cells

  1. Tissue components
    - Primary lymphoid tissue: bone marrow, thymus
    - Secondary lymphoid tissue: lymph nodes, spleen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How are immune cells classified according to progenitor cells?

A

Hematopoeitic Stem Cells
- differentiate into:

  1. Myeloid Progenitor Cells
    - RBCs
    - Platelets
    - MYELOcytes: mostly INNATE response
    + Neutrophils
    + Basophils
    + Mast cells
    + Eosinophils
    + Monocytes (Macrophages, Langerhans cells): BOTH
    + Dendritic cells: ADAPTIVE
  2. Lymphoid Progenitor Cells
    - LYMPHOcytes:
    + Natural Killer cells: INNATE
    + T-lymphocytes: CELL-mediated ADAPTIVE response
    + B-lymphocytes: ANTIBODY-mediated ADAPTIVE response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the cells involved in the INNATE immune response?

A

A. Granulocytes/Polymorphonuclear Leukocytes
- presence of granules in the cytoplasm
- multilobulated nucleus

  1. Neutrophil
    - most abundant granulocyte
    - phagocytic: bacteria, viruses
    - releases granule products and cytokines
  2. Basophils/Mast cells
    - possess high-affinity receptors for IgE
    - effector cells in IMMEDIATE hypersensitivity
    - basophils: in the blood
    - mast cells: in connective tissues
  3. Eosinophils
    - receptors for IL-5: responsible for it’s development
    - effector cells in DELAYED hypersensitivity (atopy, asthma) and parasitic infections
    - NOT a major effector cell in the eye except in helminthic infection

B. Agranulocytes
- no granules in the cytoplasm
- unilobulated nucleus

Monocytes/Macrophages: BOTH innate and adaptive
- can be activated into effector cells after exposure or phagocytosis of complement-coated pathogens or mediators
- innate: phagocytic cells that clear debris and pathogens
- adaptive: antigen-presenting cells to T-lymphocytes
- monocytes: in the blood
- macrophages: activated monocytes found in tissues
- Langerhans cells: special type in conjunctiva

C. Natural Killer cells (Non-T, Non-B cells)
- large, granular LYMPHOcytes
- cytotoxic lymphocytes involved in the INNATE response
- analogous to cytotoxic T cells of adaptive response
- provide rapid responses to viral infections, intracellular pathogens and tumor formation
- unique ability to recognize and kill stressed cells in the absence of antibodies and MHC, allowing for a much faster response
- named “natural killers” because they do not require activation to kill cells that are missing “self” markers of MHC class I.
- important because harmful cells that are missing MHC I markers cannot be detected and destroyed by other immune cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the cells involved in ADAPTIVE immune response?

A

A. Dendritic cells
- antigen-presenting or accessory cells of myeloid OR lymphoid descent
- process and present antigens to T-lymphocytes
- initiates the process of quiescence in lymphocytes

B. Lymphocytes
- requires subsequent maturation in peripheral or secondary lymphoid tissues
- classified into 3 types based on surface markers

  1. B-cells
    - develop in the BONE MARROW
    - MOST require T-cells to be present for activation
    - differentiates into:
    + Plasma cells: produce antibodies
    + Memory B-cells: for faster response in subsequent infections
    + T-independent B-cells: response to encapsulated bacteria with OPS layer enabling them to evade T-cells
  2. T-cells
    - develop in the THYMUS
    - differentiates into:
    + Cytotoxic/Killer (CD8) T-cells: directly kill virus-infected cells
    + Helper (CD4) T-cells: indirect destruction by cytokine signaling to activate B-cells
    + Memory T-cells: may either have cytotoxic or helper functions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the two basic classifications of immune responses?

A

Immune Response
- sequence of molecular and cellular events which rid the host of an offending stimulus

Innate Immune Response/Natural Immunity
- genetically PRE-PROGRAMMED NON-SPECIFIC response determined by PRE-EXISTING receptors for a WIDE range of stimuli
- produce GENERIC mediators that recruit NON-SPECIFIC effector cells
- different stimuli –> generalized response

Adaptive Immune Response
- TAILORED response elicited by NEWLY-CREATED receptors in reaction to a UNIQUE antigen
- generate antigen-SPECIFIC mediators and effector cells which only act upon the particular antigen
- specific antigen –> unique response
- lengthy process because of the antigen processing and generation of unique mediators and effectors by specialized tissues of the immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What happens when an antigen is encountered by the body?

A
  1. Recognition
    - foreign antigen is detected by receptors of the INNATE system
  2. Activation
    - activated receptors recruit pre-formed mediators and effector cells
  3. Response
    - pattern recognition and phagocytosis by macrophages
    - inflammation by recruitment of other cells of the innate response
    - maturation of macrophages and dendritic cells into antigen-presenting cells to activate the ADAPTIVE immune response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Compare the innate and adaptive immune response.

A

INNATE: non-specific stimuli producing a generalized response

Trigger: non-specific stimuli
Receptor-specificity: non-specific and pre-made
Speed: fast/hours (pre-programmed)
Effector cells: non-specific and pre-made (WBCs)
Memory: none; similar responses regardless of antigen or previous exposure

ADAPTIVE: specific stimuli producing a tailored response

Trigger: specific immunity acquired after a previous exposure
Receptor-specificity: antigen-specific
Speed: slow/days (still need processing and generation)
Effector cells: pre-made (WBCs) + antigen-specific (T and B cells)
Memory: enhanced specific response with succeeding exposures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the 3 phases of the Immune Response Arc of adaptive immunity?

A

Phase 1: Afferent Phase
- antigen stimulation, recognition and presentation

Phase 2: Processing Phase
- antigen processing in secondary lymphoid tissue (lymph nodes)

Phase 3: Efferent Phase
- production of antigen-specific mediators and effector cells to mount a tailored response directed only towards the specific antigen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Discuss the 1st Phase or the Afferent Phase of the Immune Response Arc.

A

Steps:
1. Recognition
- antigen stimulates and is recognized by pre-made receptors

  1. Transport
    - antigen is transported by APCs via lymphatic channels to the lymph node
  2. Presentation
    - antigen is presented by APCs to T-cell receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Discuss the 2nd Phase or the Processing Phase of the Immune Response Arc.

A

Processing Phase
- conversion of antigenic stimulus into an immunologic response
- APCs present antigenic fragments to the naive lymphocytes in the lymph nodes causing their differentiation and activation

Steps:
1. Helper T-cell detection
- requires trimolecular complex: APC HLA molecule + antigen fragment + T cell antigen receptor

  1. Helper T-cell activation and differentiation
    - undergo cell division, mediator synthesis and receptor expression
    - release cytokines (especially IL2) for B cell and cytotoxic T-cell activation
  2. B-cell and cytotoxic T-cell differentiation
    - begin as naive lymphocytes
    - activated by cytokine signaling from helper T-cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Discuss the 3rd Phase or the Effector Phase of the Immune Response Arc.

A
  • activated lymphocytes further secrete mediators and effectors which rid the body of the offending antigen
  • 3 possible effector responses:
    + predominantly ANTIBODY-mediated
    + predominantly CELL-mediated
    + combined mechanism

Components:
1. Naive CD8 cells –> Cytotoxic T-cells
- express CD8 surface markers
- respond to MHC Class I receptors in APCs
- destroys tumor cells and virus-infected cells
- produce cytotoxic cytokines (TGF-B) and pore-forming molecules

  1. Naive CD4 cells –> Helper T-cells
    - express CD4 surface markers
    - responds to MHC Class II receptors in APCs
    - activates naive CD8 T-cells and B-cells
    - involved in delayed hypersensitivity reactions
    - Th1 cells: produce IL2, IL12, IFN-Y, TNF-B; helps IgG secretion
    - Th2 cells: produce IL4, IL5, IL10; helps IgE and IgA secretion
    - Th17 cells: autoimmunity
    - Regulatory T-cells: suppressive immunity
  2. Naive B-cells –> Activated B-cells
    - responds to MHC Class II receptors in APCs
    - produce antibodies
    + IgA: secretory
    + IgE: allergens
    + IgG1 or 3: antibody-dependent cell-mediated cytotoxicity
    + IgG4: agglutination; delayed but long-lasting response
    + IgM: complement formation; immediate but short-lived response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are Major Histocompatibility Complex molecules?

A
  • 4-megabase region on Chromosome 6 that codes for cell surface proteins essential for the immunologic specificity, transplant rejection and autoimmunity
  • found on all antigen-presenting cells

Functions:
1. Tissue-antigen that allows the immune system to bind to, recognize, and tolerate itself (autorecognition)
2. Chaperone for intracellular peptides that are presented to T cell receptors (TCRs) as potential foreign antigens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Discuss the ANTIBODY-mediated effector response.

A
  • antibodies produce an immune response by attaching to antigens and forming immune complexes via 3 steps:
    1. Neutralization
  • blocks ability of pathogen to attach to host cell
    2. Opsonization
  • coating of pathogen with complement to enhance phagocytosis
    3. Agglutination
  • multiple Ab bind on the Ag causing the complex to precipitate or deposit

Scenarios:
1. intravascular Ab attach to circulating Ag and form circulating immune complexes
2. in conditions with altered vascular permeability: passive leakage of Ab (especially IgG) can bind to tissue-bound Ag and form complexes that deposit in the tissues
3. B cells can actively infiltrate into tissues becoming PLASMA cells and produce Ab locally

  • complex deposition in the tissues activate the complement cascade and trigger a local inflammatory response

End-point: Membrane-Attack Complex formation
- pore-like structures composed of activated complement
- attach to pathogens, forming an opening in the cell and causing cell lysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the Goldman-Whitmer coefficient?

A
  • compares the ratio of a SPECIFIC Ab in the intraocular fluid and serum to the ratio of TOTAL Ab in the two compartments
  • differentiates between local Ab production and passive leakage from the blood
  • GWC > 4: indicates local production within eye

Formula:

Specific Ab (ocular fluid)/Specific Ab (serum) ----------------------------------------------------------------
Total Ab in intraocular fluid/Total Ab in serum
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the complement cascade?

A

Complement
- plasma proteins that augment the opsonization of pathogens by antibodies and induction of inflammation
- “compliments” the antipathogenic activity of Ab
- secreted by hepatocytes and monocytes

Complement Cascade
- series of steps that result in the formation of different complement by enzyme activation
- part of the INNATE immune system: not adaptable and doesn’t change
- recruited and brought into action by Ab of the adaptive immune system
- activation of a small number of complement in the beginning is amplified with each successive reaction forming a RAPID and EXTENSIVE immune response

Pathways:
1. Classical Pathway: Ag-Ab complexes bind C1 and cleave C4 and C2 to form C3 convertase (C4BC2A)

  1. Lectin Pathway: serum lectin binds mannose in the pathogen and interacts with mannose-associate serine proteases to cleave C4 and C2 and form C3 convertase
  2. Alternative Pathway: continuously activated at low levels as a result of spontaneous C3 hydrolysis
    - doesn’t rely on pathogen-binding Ab like 1 & 2
  3. Common Pathway:
    - C3 convertase (C4BC2A) cleaves C3 into:
    + C3A: anaphylatoxin (for inflammation)
    + C3B: for opsonization
    - another C3B binds to C3 convertase to form C5 convertase (C4BC2AC3B) which cleaves C5 into:
    + C5A: anaphylatoxin (for inflammation)
    + C5B: initiates formation of MAC
  4. Terminal Pathway
    - initiated by C5B
    - formation of Membrane-Attack Complex (C5BC6C7C8C9)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the Membrane Attack Complex?

A
  • pore-like structure composed of complements C5B, C6, C7, C8 and multiple copies of C9
  • binds to the outer surface of the plasma membranes of pathogens to form transmembrane channels which disrupt the membrane and cause cell lysis
17
Q

What are the three ways in which complement activation can protect the body from pathogens?

A
  1. Anaphylatoxins: C3A, C5A
    - small fragments of complement that act as chemoattractants to recruit more phagocytes and inflammatory cells to the site of complement activation
  2. Opsonization
    - large numbers of activated complement generated by the cascade bind covalently to pathogens, enhancing the phagocytic capabilities of macrophages
  3. Membrane-Attack-Complex: C5B, C6, C7, C8, C9
    - final product of the terminal pathway
    - pore-forming structure that causes cell lysis and death
18
Q

Discuss the LYMPHOCYTE-mediated effector response.

A

A. CD4/Helper T-cells
- responds to MHC Class II receptors in APCs
- activates naive CD8 T-cells and B-cells
- prototype: delayed hypersensitivity reactions

  1. Th1-Mediated
    - responsible for Delayed (IV) Hypersensitivity
    - produce IL2, IL12, IFN-Y, TNF-B
    - helps IgG secretion
    - examples:
    + intracellular and fungal infections
    + T-cell mediated autoimmune diseases
    + transplant rejection
    + PPD reaction
  2. Th2-Mediated
    - produce IL4, IL5, IL10
    - helps IgE and IgA secretion
    - examples:
    + parasitic infections
    + allergic reactions
    + asthma
    + atopy

B. CD8/Cytotoxic T-cells
- respond to MHC Class I receptors in APCs
- interacts with IL2 and IL12 produced by helper T-cells
- kills infected cells by:
1. Perforins: glycoproteins responsible for pore formation in cell membranes causing cell lysis
2. Fas ligand: member of the TNF family that induces apoptosis

19
Q

What is Immune Tolerance?

A
  • state of immune UNRESPONSIVENESS to self antigens
  • in effect, the immune system should NOT attack the body’s own cells
  • loss leads to Autoimmune Diseases
  1. CENTRAL Immune Tolerance
    - occurs during lymphocyte development in the thymus (T-cells) and bone marrow (B-cells)
    - T-cells and B-cells that can bind to self-antigens are eliminated or differentiated into regulatory T cells
    - prevents the maturation of autoreactive lymphocytes
  2. PERIPHERAL Immune Tolerance
    - occurs after release of mature lymphocytes into the lymph nodes or peripheral tissues
    - regulatory T cells induce suppression of autoreactive cells that have escaped the mechanisms of central tolerance
20
Q

What are immunologic microenvironments and regional immunity?

A
  • each organ and tissue has it’s own immunologic microenvironment and particular immune response arc
  • regional immunity exists because of the different immunologic microenvironments in the different organ systems of the body
21
Q

What comprise the anatomic immunologic ocular barriers?

A
  1. Blood-Retina Barrier: tight junctions
    - OUTER: between RPE cells
    - INNER: between retinal vessel endothelium
  2. Blood-Aqueous Barrier: tight junctions between inner NON-pigmented epithelium of the ciliary body and posterior pigmented epithelium of the iris
  3. Limited afferent delivery of local antigens to lymph nodes
  4. Immunosuppressive ocular microenvironment
22
Q

Where are the different ocular immune microenvironments?

A
  • even within the eye, there exists regional differences in ocular immunity
  1. Conjunctiva
  2. Cornea and sclera
  3. Anterior chamber, iris, ciliary body and vitreous
  4. Retina, RPE and choroid
23
Q

Describe the immunologic microenvironment of the conjunctiva.

A

+ (+) lymphatics
+ resident APCs: dendritic cells, Langerhans cells and macrophages
+ specialized immune compartment: follicles
+ resident effector cells: mast cells, T-cells, B-cells, RARE PMNs
+ resident effector molecules: ALL (mostly IgE, IgG, IgA and complement)
+ immunoregulation: Mucosa-Associated Lymphoid Tissue (MALT)

24
Q

Describe the immunologic microenvironment of the cornea and sclera.

A

+ lymphatics and Langerhans cells ONLY at limbus
+ NO APCs in the central cornea and sclera
+ NO specialized immune compartments and resident effector cells

25
Q

Lymphatics are present only in which areas of the eye?

A
  1. Conjunctiva
  2. Limbus
  3. Sclera
  4. Choriocapillaris

NO Lymphatics in the:
- anterior chamber
- vitreous
- retina
- iris
- ciliary body
- choroid

26
Q

Describe the immunologic microenvironment of the anterior chamber, vitreous, iris and ciliary body.

A

+ Anterior Chamber-Associated Immune Deviation (ACAID)

+ Aqueous: contain mix of factors that suppress immune response

+ Vitreous: can electrostatically bind charged proteins which serve as antigen depots and substrates for leukocyte adhesion

+ NO lymphatics:
- if antigen is soluble: cleared through TM with AH
- if insoluble or particles: via endocytosis by TM endothelial cells or macrophages

+ Partial Blood-Uveal Barrier
- FENESTRATED capillaries of the CB: produces a size-dependent concentration gradient with abundance of small molecules
- TIGHT JUNCTIONS between the apices of the INNER and OUTER ciliary epithelium prevent interstitial molecules to permeate into the AH

+ Resident APCs: dendritic cells and macrophages in iris and CB

+ NO specialized immune compartments

+ RARE T-cells and mast cells. NO B-cells, PMNs and eosinophils

+ MINIMAL antibodies but WITH kallikrein and complement

27
Q

What is the ocular immune privilege?

A
  • ability of the eye to curb and control the immune response to protect itself from damage
  • tissue may be grafted with minimal risk of rejection
  • due to paucity of immune response elements

Contributors:
1. Separation of the eye from the immune system by the BRB
2. Immunosuppressive intraocular microenvironment
3. Eye-induced stimulation of immunosuppressive regulatory T cells by TGF-B

Example: Ocular relapse of leukemia
- cancer cells hide in the eye
- systemic chemotherapy cannot enter the eye
- treatment: local radiotherapy or intravitreal chemotherapy

28
Q

What is Anterior Chamber-Associated Immune Deviation?

A
  • altered form of SYSTEMIC immunity to an antigen after immunization by an anterior chamber injection
  • immunoregulatory microenvironment of the eye downregulates the activation and function of systemic immunologic effectors
    + delayed-type hypersensitivity reactions and antibody production are SUPPRESSED
    + cytotoxic T-cell activity is NOT AFFECTED
  • eliminated by Splenectomy

Causes:
1. Immunoregulatory cytokines (TGF-B), neuropeptides and complement inhibitors found in the aqueous and uveal tissue
2. Functionally-altered APCs

Afferent Phase:
- Ag are recognized and taken up by functionally-altered uveal macrophages as a result of immunosuppressive mediators
- macrophages leave the eye via the TM into the venous circulation to the spleen

Processing Phase:
- processing of the Ag in the spleen activates helper T cells, regulatory T cells and B cells

Efferent Phase:
- regulatory T cells downregulate the helper T cell response to the Ag in ALL body sites causing:
1. immunosuppression of Ag-specific delayed hypersensitivity
2. selective decrease production of complement-fixing antibodies

29
Q

Describe the immunologic microenvironment of the retina and choroid.

A

+ Immune privileged site

+ NO lymphatics

+ Blood-Retina Barrier

+ Resident APCs:
- retina: microglia
- choroid: dendritic cells, macrophages

+ NO specialized immune compartments

+ Resident effectors:
- retina: NO lymphocytes; RARE to NO immunoglobulins
- choroid: mast cells, FEW lymphocytes; IgG and IgA

30
Q

What are experimental autoimmune uveitis models?

A
  • animal models of uveitis induced by immunization of animals with:
    1. retinal antigens AND
    2. bacterial adjuvants:
    + innate: triggers bacterial pattern recognition receptors
    + adaptive: provides proinflammatory substances
31
Q

What are the most common uveitogenic retinal proteins used for EAU models?

A
  1. Arrestin
    - Retinal Soluble Antigen/S-Ag
    - found in photoreceptors
    - binds to rhodopsin to prevent coupling with transducin and activation of cGMP phosphodiesterase
    - induces an ACUTE, SEVERE inflammatory response with COMPLETE destruction of the photoreceptor layer
  2. Interphotoreceptor Retinoid Binding Protein (IRBP)
    - glycoprotein in the interphotoreceptor matrix between the NSR and RPE
    - role in the retinoid transport between the PRL and RPE
    - causes CHRONIC, INSIDIOUS response with LESS vitreous inflammation
  3. Others:
    - Rhodopsin and Opsin (less uveitogenic form)
    - Recoverin
    - Phosducin
32
Q

What are the 4 types of induced mouse EAU models?

A
  1. Classical EAU
    - agent: Complete Freund’s Adjuvant (desiccated TB) + IRBP
    - presentation: CHRONIC uveoretinitis
  2. Endotoxin-Induced EAU
    - agent: Bacterial Lipopolysaccharide
    - presentation: ACUTE ANTERIOR uveitis
    - rapid onset, short duration, INNATE immune response ONLY
  3. Humanized EAU
    - agent: Complete Freund’s Adjuvant + Arrestin
    - presentation: POSTERIOR uveitis
    - involves BOTH innate and adaptive immune response
  4. Melanin-induced Uveitis
    - agent: Melanin components or tyrosinase-related proteins 1 & 2
    - presentation: VKH-like illness (iridocyclitis + choroiditis + hypopigmentation)
    - delayed onset, chronic, ADAPTIVE immune response ONLY
33
Q

What is Vogt-Koyanagi-Harada disease?

A
  • bilateral granulomatous panuveitis with or without extraocular s/sx
  • due to T-cell mediated autoimmune reaction against Ag associated with melanocytes, melanin or the RPE
34
Q

What are the mechanisms driving spontaneous uveitis in healthy individuals?

A
  1. Deficient central and peripheral tolerance leads to the presence of NON-TOLERANT retinal Ag-specific T-cells in HEALTHY individuals.
  2. Non-tolerant T-cells become activated and acquire effector functions after escaping the control of regulatory T-cells.
  3. T-cells undergo clonal expansion with some reaching the eye where they resist the local immunosuppressive microenvironment and cause a breakdown of the BRB.
  4. Activation of the retinal vasculature causes recruitment of more inflammatory effector cells and molecules.
  5. Resulting inflammation damages the other ocular tissues causing further leakage of ocular Ag which triggers eye-dependent systemic and local regulatory mechanisms that eventually contain and terminate the disease.
35
Q

What HLA genes are associated with development of uveitis?

A
  • evidence of genetic association and susceptibility to uveitis development
  • risk factors:
    1. histocompatibility antigens
    2. ethnicity
    3. family history

Arrestin
1. Birdshot retinochoroidopathy: HLA A29; European
2. Behcet disease: HLA B51; Both
3. Anterior uveitis with ankylosing spondylitis: HLA B27; European

Melanin-related antigens
1. VKH disease: HLA DPB/DQA/DQB/DRB; Asians
2. Sympathetic ophthalmia: HLA DRB; Any ethnicity

36
Q

What is the pathophysiology of Uveitis-Glaucoma-Hyphema syndrome?

A
  • major cause of inflammation post-cataract surgery and IOL implantation
  • cause: presence of certain IOL configurations especially ACIOL made of PMMA
  • IOL causes chaffing or trauma to the iris or ciliary body
  • INNATE immune response is activated causing the release of cytokines and eicosanoids that alter vascular permeability, facilitating the entry of complement and fibrin
37
Q

What is the pathophysiology of retinal vasculitis in SLE?

A
  • cause: DNA and histones from damaged cells trapped in the basement membranes of blood vessel walls
  • circulating anti-dsDNA IgG autoantibodies bind the antigen and activate the complement cascade
  • local immune complexes are formed and deposited in the vessel walls and extravascular tissues further recruiting more effector cells in the inflammation site
  • (+) Vascular Sheathing: due to infiltration of the vessels walls and adjacent tissues by PMNs and macrophages
38
Q

What is the pathophysiology of sympathetic ophthalmia?

A
  • autoimmune bilateral panuveitis
  • inciting cause: penetrating trauma or monocular surgery causing damage to the uvea
  • uveal antigens, normally isolated behind the BRB, are suddenly exposed to the immune system
  • APCs phagocytose ocular protein antigens and carries them to the lymph nodes or spleen for presentation to and processing by helper T cells

2 Scenarios:

  1. NORMAL individuals
    - Th cells should NOT recognize these as NON-self because autoreactive T cells should have been destroyed in the thymus
  2. PREDISPOSED individuals
    - autoreactive T-cells escape because of deficient CENTRAL tolerance OR the Ag may resemble a similar Ag in previous infections
    - autoreactive Th cells clonally expand, migrate to the site of inflammation and enter the eye through the damaged BRB to mount an inflammatory response
    - cytokine release leads to recruitment of more effector cells and molecules overwhelming the immunosuppressive capacity of the intraocular microenvironment
    - autoreactive Th cells then infiltrate the undamaged, SYMPATHIZING eye and elicit inflammation by systemic cytokine stimulation
39
Q

What are the treatment modalities for uveitis?

A
  1. Glucocorticosteroids
    - MAINSTAY of treatment
    - bind intracellular receptors and translocate into the nucleus where it alters DNA transcription
    - systemic: alters homing pattern of T-cells and other effector cells, preventing their recruitment to inflammation sites
    - local: inhibition of inflammatory mediator synthesis or release by effector cells
  2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    - used only as an ADJUNCT
    - prevent the conversion of arachidonic acid to prostaglandins, thromboxane and prostacyclins by inhibiting cyclooxygenase
    - MILD anti-inflammatory effects
  3. Alkylating agents [Cyclophosphamide, Chlorambucil]
    - prevents cell division by cross-linking an alkyl group with DNA
    - prevents the bone marrow from replenishing lymphocytes and other effector cells
  4. Antimetabolites [Methotrexate, Azathioprine, Mycophenolate]
    - blocks purine ring formation essential in protein synthesis and cell division by inhibiting folate metabolism
    - suppresses the activation, differentiation and expansion of effector cells in the lymphoid tissues and bone marrow
  5. Calcineurin inhibitor [Cyclosporine]
    - blocks T-cell activation and differentiation
  6. Biologics
    - target specific molecules: monoclonal Ab, soluble receptors or cytokine inhibitors
    - SECOND-LINE treatment indicated in:
    + inadequate response
    + intolerance to conventional treatments
    - Anti-TNF-alpha: Infliximab, Etanercept, Adalimumab
    - Anti-IL6: Tocilizumab
    - Anti-VEGF: Bevacizumab
    - Anti-CD25 (T-cell inhibitor): Daclizumab
    - Anti-CD20 (B-cell inhibitor): Rituximab